10.6084/M9.FIGSHARE.21257131
Camila de Almeida Velozo
Camila de Almeida
Velozo
Federal University of Rio de Janeiro
Flávia Rachel Moreira Lamarão
Flávia Rachel Moreira
Lamarão
Lucia Elena Alvarado-Arnez
Lucia Elena
Alvarado-Arnez
Oswaldo Cruz Foundation
Cynthia Chester Cardoso
Cynthia Chester
Cardoso
Oswaldo Cruz Foundation
Federal University of Rio de Janeiro
Pharmacogenetics of HIV therapy: State of the art in Latin American countries
<div><p>Abstract The use of combined antiretroviral therapy (cART) has resulted in a remarkable reduction in morbidity and mortality of people living with HIV worldwide. Nevertheless, interindividual variations in drug response often impose a challenge to cART effectiveness. Although personalized therapeutic regimens may help overcome incidence of adverse reactions and therapeutic failure attributed to host factors, pharmacogenetic studies are often restricted to a few populations. Latin American countries accounted for 2.1 million people living with HIV and 1.4 million undergoing cART in 2020-21. The present review describes the state of art of HIV pharmacogenetics in this region and highlights that such analyses remain to be given the required relevance. A broad analysis of pharmacogenetic markers in Latin America could not only provide a better understanding of genetic structure of these populations, but might also be crucial to develop more informative dosing algorithms, applicable to non-European populations.</p></div>
60199 Biochemistry and Cell Biology not elsewhere classified
60499 Genetics not elsewhere classified
SciELO journals
2022
2022-10-01
2022-10-01
Dataset
261156 Bytes
10.1590/1678-4685-gmb-2022-0120
CC BY 4.0